{"id":65289,"date":"2026-05-14T13:57:40","date_gmt":"2026-05-14T05:57:40","guid":{"rendered":"https:\/\/flcube.com\/?p=65289"},"modified":"2026-05-14T13:57:40","modified_gmt":"2026-05-14T05:57:40","slug":"hengrui-pharma-launches-phase-ib-ii-trial-of-novel-triple-combination-therapy-shr-3821-with-adebrelimab-and-reltirafusp-alfa-targets-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65289","title":{"rendered":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced it has received regulatory approval in China to initiate a <strong>Phase Ib\/II clinical study<\/strong> evaluating its proprietary <strong>SHR-3821<\/strong> in combination with <strong>adebrelimab<\/strong> and <strong>retlirafusp alfa<\/strong> for the treatment of <strong>advanced solid tumors<\/strong>. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-framework\">Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Development Stage<\/th><th>Mechanism of Action<\/th><th>Regulatory Status<\/th><\/tr><\/thead><tbody><tr><td><strong>SHR-3821<\/strong><\/td><td>Phase Ib\/II (novel)<\/td><td>Selective activation of tumor-infiltrating immune cells<\/td><td>First-in-class in China (no approved competitors)<\/td><\/tr><tr><td><strong>Adebrelimab<\/strong><\/td><td>Approved (Feb 2023)<\/td><td>Anti-PD-L1 monoclonal antibody blocking PD-1\/PD-L1 pathway<\/td><td>Approved for extensive-stage SCLC (1L with chemo)<\/td><\/tr><tr><td><strong>Reltirafusp Alfa<\/strong><\/td><td>Approved (Jan 2026)<\/td><td>PD-L1\/TGF-\u03b2RII fusion protein dual targeting<\/td><td>Approved for gastric\/GEJ adenocarcinoma (1L with chemo)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-shr-3821-novel-immune-cell-activator\">SHR-3821 \u2013 Novel Immune Cell Activator<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> In-house developed antibody drug for advanced solid tumors<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First-in-class<\/strong> mechanism in China with no approved competitors targeting the same pathway<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selectively activates immune cells specifically within tumor tissue microenvironment<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Tumor-localized immune activation potentially reduces systemic toxicity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-adebrelimab-established-pd-l1-inhibitor\">Adebrelimab \u2013 Established PD-L1 Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Humanized anti-PD-L1 monoclonal antibody developed independently by Hengrui<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks PD-1\/PD-L1 pathway responsible for tumor immune tolerance<\/li>\n\n\n\n<li><strong>Commercial Status:<\/strong> Already approved in China for first-line extensive-stage small cell lung cancer (February 2023)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-reltirafusp-alfa-dual-targeting-fusion-protein\">Reltirafusp Alfa \u2013 Dual-Targeting Fusion Protein<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> PD-L1\/TGF-\u03b2RII fusion protein designed for enhanced immune activation<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong><\/li>\n\n\n\n<li>Promotes activation of effector T cells through PD-L1 targeting<\/li>\n\n\n\n<li>Improves immune regulation in tumor microenvironment via TGF-\u03b2RII inhibition<\/li>\n\n\n\n<li><strong>Recent Approval:<\/strong> January 2026 for first-line gastric\/gastroesophageal junction adenocarcinoma with PD-L1 positivity (CPS \u2265 1)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-triple-combination\">Strategic Rationale for Triple Combination<\/h2>\n\n\n\n<p>This innovative combination leverages complementary mechanisms to address multiple layers of tumor immune suppression:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>SHR-3821<\/strong> provides localized immune cell activation within the tumor<\/li>\n\n\n\n<li><strong>Adebrelimab<\/strong> removes the primary immune checkpoint blockade (PD-L1)<\/li>\n\n\n\n<li><strong>Reltirafusp alfa<\/strong> simultaneously targets both PD-L1 and TGF-\u03b2 pathways, addressing additional immunosuppressive factors in the tumor microenvironment<\/li>\n<\/ol>\n\n\n\n<p>The triple approach aims to create a synergistic effect that overcomes the limitations of single-agent or dual-combination immunotherapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-advantage\">Market Context &amp; Competitive Advantage<\/h2>\n\n\n\n<p><strong>China&#8217;s Immunotherapy Landscape:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rapidly evolving market with increasing adoption of combination immunotherapy approaches<\/li>\n\n\n\n<li>High unmet need in advanced solid tumors resistant to existing immunotherapies<\/li>\n\n\n\n<li>Regulatory preference for domestically developed innovative therapies<\/li>\n<\/ul>\n\n\n\n<p><strong>Hengrui&#8217;s Integrated Portfolio Strategy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>All three components are <strong>internally developed<\/strong>, providing complete control over development and commercialization<\/li>\n\n\n\n<li>Leverages existing commercial infrastructure for adebrelimab and retlirafusp alfa<\/li>\n\n\n\n<li><strong>First-in-class potential<\/strong> for SHR-3821 creates significant competitive moat<\/li>\n\n\n\n<li>Triple combination could establish new standard of care if successful<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-commercial-outlook\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<p>The Phase Ib\/II trial will assess safety, tolerability, and preliminary efficacy of the triple combination. Given the established safety profiles of adebrelimab and retlirafusp alfa, the primary focus will be on determining optimal dosing of SHR-3821 and evaluating synergistic anti-tumor activity.<\/p>\n\n\n\n<p>Success in this trial could position Hengrui to pursue accelerated approval pathways for multiple solid tumor indications, leveraging the company&#8217;s growing expertise in combination immunotherapy development.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of the triple combination therapy. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260514_I0K5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260514_I0K5.\"><\/object><a id=\"wp-block-file--media-ed6f207a-41cf-4bd9-8623-0cd836d1fbed\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260514_I0K5.pdf\">600276_20260514_I0K5<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260514_I0K5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ed6f207a-41cf-4bd9-8623-0cd836d1fbed\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,2586,4228,852],"class_list":["post-65289","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65289\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65289\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T05:57:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma Launches Phase Ib\\\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors\",\"datePublished\":\"2026-05-14T05:57:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289\"},\"wordCount\":556,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65289#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65289\",\"name\":\"Hengrui Pharma Launches Phase Ib\\\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T05:57:40+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\\\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65289\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65289#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma Launches Phase Ib\\\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65289","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.","og_url":"https:\/\/flcube.com\/?p=65289","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T05:57:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65289#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65289"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors","datePublished":"2026-05-14T05:57:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65289"},"wordCount":556,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65289#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65289","url":"https:\/\/flcube.com\/?p=65289","name":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T05:57:40+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib\/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65289#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65289"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65289#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma Launches Phase Ib\/II Trial of Novel Triple Combination Therapy \u2013 SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65289"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65289\/revisions"}],"predecessor-version":[{"id":65292,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65289\/revisions\/65292"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}